BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld Asia
Home
» Regulatory actions for April 21-27, 2020
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Regulatory actions for April 21-27, 2020
April 28, 2020
No Comments
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Algernon, Arch Biopartners, Beigene, Biontech, Biosig Technologies, Caladrius, Carsgen, Chugai, Clarity, Cstone, Diffusion, Eli Lilly, Halozyme, Hope Biosciences, Immuneoncia, Innovent Biologics, Janssen, Mateon, Oryzon Genomics, Pfizer, Rafael, Revive, Samsung Biologics, Shanghai Green Valley, Takeda, Viralclear, Vitro Diagnostics.
BioWorld Asia
Briefs
Regulatory actions